- Home
- HBAN vs NTRA Comparison
HBAN vs NTRA Comparison
Compare HBAN & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- NTRA
- Stock Information
- Founded
- HBAN 1866
- NTRA 2003
- Country
- HBAN United States
- NTRA United States
- Employees
- HBAN N/A
- NTRA N/A
- Industry
- HBAN Major Banks
- NTRA Medical Specialities
- Sector
- HBAN Finance
- NTRA Health Care
- Exchange
- HBAN Nasdaq
- NTRA Nasdaq
- Market Cap
- HBAN 23.1B
- NTRA 20.6B
- IPO Year
- HBAN N/A
- NTRA 2015
- Fundamental
- Price
- HBAN $16.32
- NTRA $161.01
- Analyst Decision
- HBAN Buy
- NTRA Strong Buy
- Analyst Count
- HBAN 18
- NTRA 15
- Target Price
- HBAN $17.36
- NTRA $152.67
- AVG Volume (30 Days)
- HBAN 14.3M
- NTRA 1.2M
- Earning Date
- HBAN 01-17-2025
- NTRA 11-12-2024
- Dividend Yield
- HBAN 3.80%
- NTRA N/A
- EPS Growth
- HBAN N/A
- NTRA N/A
- EPS
- HBAN 1.03
- NTRA N/A
- Revenue
- HBAN $6,690,000,000.00
- NTRA $1,531,955,000.00
- Revenue This Year
- HBAN N/A
- NTRA $53.06
- Revenue Next Year
- HBAN $5.31
- NTRA $11.04
- P/E Ratio
- HBAN $15.84
- NTRA N/A
- Revenue Growth
- HBAN N/A
- NTRA 54.94
- 52 Week Low
- HBAN $12.02
- NTRA $58.53
- 52 Week High
- HBAN $18.45
- NTRA $175.63
- Technical
- Relative Strength Index (RSI)
- HBAN 38.49
- NTRA 45.49
- Support Level
- HBAN $16.99
- NTRA $153.53
- Resistance Level
- HBAN $17.30
- NTRA $172.80
- Average True Range (ATR)
- HBAN 0.39
- NTRA 5.91
- MACD
- HBAN -0.23
- NTRA -2.98
- Stochastic Oscillator
- HBAN 23.00
- NTRA 8.17
About HBAN Huntington Bancshares Incorporated
Huntington is a regional us bank with around $200 billion in assets (as of September 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.